Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial전문 간호 및 생활 보조 시설의 거주자와 직원 간의 COVID-19 발생에 대한 밤라니비맙 대 위약의 효과: 무작위 임상 시험Randomized Controlled Trial Published on 2021-07-062022-09-14 Journal: JAMA [Category] SARS, 신약개발, 임상, 진단, 치료제, [키워드] adverse event age bamlanivimab baseline clinical Combination common adverse event COVID-19 COVID-19 severity database lock death defined determine disease severity double-blind Effect Efficacy enrolled hypertension incidence incidence of COVID-19 index case Infection Intervention Mild moderate monoclonal antibody monotherapy Neutralizing Nursing occurred Odds ratio outbreak outcome participant phase 3 trial Placebo Primary outcome PROTECT randomization Randomized reached receive reduced reported Research resident risk safety population SARS-CoV-2 SARS-COV-2 infection secondary outcome serology significantly single intravenous infusion staff the placebo group the United State therapy Treatment triggered urinary tract infection viral strain women [DOI] 10.1001/jama.2021.8828 PMC 바로가기 [Article Type] Randomized Controlled Trial
Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy레스베라트롤-아연 나노입자 또는 프테로스틸벤-아연: 잠재적인 COVID-19 단일 및 보조 요법Article Published on 2021-07-012022-09-11 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] 치료제, [키워드] adjuvant therapy administration Anti-inflammatory antioxidant clinical trial Combination COVID-19 dark chocolate disease Diseases drug drug delivery systems Inflammatory management manuscript Mild moderate-severe monotherapy Nanotechnology nutraceuticals peanut butter Potential Prevent progression pterostilbene Red wine resveratrol suggested therapy Trial Zinc [DOI] 10.1016/j.biopha.2021.111626 PMC 바로가기 [Article Type] Article
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry류마티스 질환이 있는 사람의 COVID-19 관련 사망과 관련된 요인: COVID-19 Global Rheumatology Alliance 의사 보고 레지스트리의 결과Article Published on 2021-07-012022-09-12 Journal: Annals of the rheumatic diseases [Category] Fulltext, SARS, 진단, [키워드] 1.26 95% CI age Alliance antirheumatic agents association Autoimmune Autoimmune diseases cardiovascular disease caution Comorbidities covariate COVID-19 COVID-19-related death Cyclophosphamide death determine died disease Disease activity Disease diagnosis dosage dosages Epidemiology Factor female glucocorticoid Glucocorticoids Health Health care higher odd highlight hypertension Immunosuppressant immunosuppressants Lung disease Male sex medication medications methotrexate monotherapy multivariable logistic regression Older age Other outcome outcome assessment Patient Primary outcome receiving required Rheumatic diseases rituximab Sex smoking status stratified sulfasalazine [DOI] 10.1136/annrheumdis-2020-219498 PMC 바로가기 [Article Type] Article
Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional StudyArticle Published on 2021-06-232022-10-27 Journal: Antibiotics [Category] COVID-19, [키워드] bacterial co-infection Bacterial infection bloodstream infection BSI Ceftaroline characteristics of patients clinical response Combination conducted coronavirus disease COVID-19 COVID-19 patients cross-sectional Diagnosis etiological hospital Hospitalized Improving indication Italy monotherapy MOST MRSA pandemic Patient patients patients with COVID-19 Pneumonia receiving Registered single-center Staphylococcus aureus therapy was used were given [DOI] 10.3390/antibiotics10070763 PMC 바로가기 [Article Type] Article
Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung CancerReview Published on 2021-06-182022-10-28 Journal: Biomedicines [Category] COVID-19, [키워드] active against acute respiratory syndrome anti-SARS-CoV-2 baicalein Cancer celastrol Combination contagious coronavirus coronavirus disease COVID-19 demonstrated drug drugs food Health highest individuals International lung cancer Lung diseases malignant tumor monotherapy mortality rate natural natural product natural remedy pandemic public health emergency Remdesivir resveratrol SARS-CoV-2 starting point Therapies Treatment United States Food and Drug Administration-approved drug widespread [DOI] 10.3390/biomedicines9060689 PMC 바로가기 [Article Type] Review
He-Jie-Shen-Shi Decoction as an Adjuvant Therapy on Severe Coronavirus Disease 2019: A Retrospective Cohort and Potential Mechanistic StudyPharmacology Published on 2021-06-182022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] acute respiratory distress acute respiratory distress syndrome adjuvant Analysis ARDS Bupleurum can be used CCL2 Chinese Clinical efficacy Clinical practice combination therapy component composed conducted coronavirus disease Coronavirus disease 2019 COVID-19 Cytoscape Decoction Effect endothelial Fever GeneCard Glycyrrhiza uralensis growth factor he-jie-shen-shi decoction IL1B Inflammatory response inheritance inhibiting viral replication involved KEGG Kyoto Ligand Lung injury Man MAPK MAPK signaling MAPK3 mechanism mechanisms Medicine monotherapy Necrosis Negative conversion network network pharmacology nine notable nucleic acid oxidative stress p53 pathway Pathways Patient Pharmacology Pinellia ternata Potential PPI predict Protein Protein–protein interaction PTGS2 receptor required Result retrospective cohort study screened Scutellaria baicalensis selected severe COVID-19 shown suggested syndrome System T cell receptor target TCMSP therapeutic therapy TNF Toll-like receptor Tongji Hospital TP53 Traditional Traditional Chinese medicine treat Vascular VEGF VEGFA Wuhan [DOI] 10.3389/fphar.2021.700498 PMC 바로가기 [Article Type] Pharmacology
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2Brief Communication Published on 2021-05-262022-10-04 Journal: Nature Medicine [Category] MERS, SARS, 변종, [키워드] administration adverse event anti-PD1 association blockade BNT162b2 Cancer Cancer immunotherapy Colon cancer Colorectal cancer coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccine CRS cytokine level Cytokine release syndrome Diagnosis elevated evidenced favor Immune checkpoint inhibitors include inflammatory markers monotherapy mRNA mRNA vaccine mRNA vaccines occurred Patient Patients with cancer Pfizer-BioNTech raised reported RNA vaccines Support syndrome vaccination [DOI] 10.1038/s41591-021-01387-6 PMC 바로가기 [Article Type] Brief Communication
Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control studyCOVID-19로 입원한 환자에서 favipiravir 치료의 이점: 후향적 관찰 사례-대조군 연구Observational Study Published on 2021-05-252022-09-10 Journal: Virology Journal [Category] SARS, 임상, 치료제, [키워드] absence added addition Antiviral effect antiviral effects antiviral therapy C-reactive protein C-reactive protein (CRP Clinical deterioration clinical outcomes cohort study Combination COVID-19 decrease defined determine Efficacy ENhance evaluate Favipiravir FPV greater group hospitalized patient Hydroxychloroquine improve clinical outcomes management monotherapy not improved offer Patient patients treated PCR negativity Pneumonia positive progression radiological regimen respiratory Result retrospective Retrospective study severe acute respiratory syndrome coronavirus 2 single-center specific treatment survival survival time the disease the timing therapy three groups Treatment Turkey was performed with COVID-19 [DOI] 10.1186/s12985-021-01577-1 PMC 바로가기 [Article Type] Observational Study
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomizationUPMC OPTIMISE-C19(COVID-19에 대한 평가를 통한 단일 클론 항체의 치료 및 영향 최적화) 시험: 반응 적응형 무작위 배정이 포함된 개방형, 실용적, 비교 효과 플랫폼 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-05-252022-09-01 Journal: Trials [Category] SARS, 변종, 임상, 진단, [키워드] adaptive Administered administration aggregate authorization bamlanivimab Bayesian blinded Blinding calculated captures Casirivimab collected Comorbidities comparator composite endpoint Course COVID-19 criteria dependent on determine determined by dissemination distribution Dosing drug Effectiveness effort element eligibility criteria Emergency emergency department Emergency Departments etesevimab EUA evaluate evaluated FDA Final Follow-up food futility Government high risk hospital Hospitalization Hospitalized Identifier Imdevimab Impact include increase in inferiority infusion Intervention investigator investigators mAbs manuscript medical record Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 monoclonal antibodies monoclonal antibody monotherapy number obese objective Open-label outcome outcome assessor outcome assessors oxygen pandemic participant Patient physician Platform trial Pragmatic pragmatic trial Primary outcome protocol provide random random allocation randomised randomised controlled trial randomization reached receive recorded recruitment routine clinical care Sample Sample size SARS-CoV-2 variant SARS-CoV-2 variants severe COVID-19 statistical statistical inference status Study protocol submission supplementary material supply sustained Symptoms System the patient the United State therapeutic Treatment treatment of COVID-19 Trial Trial registration United States US Food and Drug Administration Version Volume website [DOI] 10.1186/s13063-021-05316-3 PMC 바로가기 [Article Type] Letter
In vitro safety “clinical trial” of the cardiac liability of drug polytherapyArticle Published on 2021-05-032022-10-04 Journal: Clinical and translational science [Category] SARS, 임상, [키워드] accelerate antioxidant arrhythmia authorization biologic Biomarker Chronic exposure clinical measurements clinical trial clinical trials clinician Concordance contractile coronavirus disease COVID‐19 decrease drug drug response Drug screening Effect elicited Emergency FDA food HCQ heart muscle help Hydroxychloroquine include increase in Infection monotherapy morphology MPS outcomes Patient Phase I platform pluripotent stem cells Potential predicted QT interval QT prolongation Repurposed drugs Safe SARS‐CoV‐2 serum tissue treat trials was measured [DOI] 10.1111/cts.13038 PMC 바로가기 [Article Type] Article